Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 518-521

  Sekine, Ikuo ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Kunitoh, Hideo ^a   Ohe, Yuichiro ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Non small cell lung cancer; Postoperative recurrence; Stage IV disease

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; CANCER STAGING; COMPARATIVE STUDY; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 67649391496     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819c7bc9     Document Type: Article

References (9)

1. Yoshino I, Yohena T, Kitajima M, et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 2001;7:204-209.
2. Travis W, Colby T, Corrin B, Shimosato Y. Histological Typing of Lung and Pleural Tumors, 3rd Ed. Berlin: Springer, 1999.
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
4. Armitage P, Berry G, Matthews J. Survival analysis. In Armitage P, Berry G, Matthews J, (Eds.), Statistical Methods in Medical Research, 4th Ed. Oxford: Blackwell Science Ltd, 2002. Pp. 568-590.
5. Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-466. (Pubitemid 351630271)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
7. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
8. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183. (Pubitemid 41702636)
9. Ichinose Y, Yano T, Yokoyama H, et al. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994;108:158-161. (Pubitemid 24224272)